Takamizawa, Shigemasa
15  results:
Search for persons X
?
10

Abstracts from the 15th International Myopia Conference:

Alexandra Benavente-Perez ; Ann Nour ; Tobin Ansel...
http://link.springer.com/article/10.1186/s40662-016-0057-3.  , 2016
 
?
11

Additional file 2 of Neutrophil-to-lymphocyte ratio as a pr..:

Shigemasa Takamizawa (11680098) ; Tatsunori Shimoi (4642615) ; Natsuko Satomi-Tsushita (7344965)...
https://figshare.com/articles/journal_contribution/Additional_file_2_of_Neutrophil-to-lymphocyte_ratio_as_a_prognostic_factor_for_patients_with_metastatic_or_recurrent_breast_cancer_treated_using_capecitabine_a_retrospective_study/18393324.  , 2022
 
?
12

Additional file 1 of Neutrophil-to-lymphocyte ratio as a pr..:

Shigemasa Takamizawa (11680098) ; Tatsunori Shimoi (4642615) ; Natsuko Satomi-Tsushita (7344965)...
https://figshare.com/articles/journal_contribution/Additional_file_1_of_Neutrophil-to-lymphocyte_ratio_as_a_prognostic_factor_for_patients_with_metastatic_or_recurrent_breast_cancer_treated_using_capecitabine_a_retrospective_study/18393321.  , 2022
 
?
13

Additional file 3 of Neutrophil-to-lymphocyte ratio as a pr..:

Shigemasa Takamizawa (11680098) ; Tatsunori Shimoi (4642615) ; Natsuko Satomi-Tsushita (7344965)...
https://figshare.com/articles/journal_contribution/Additional_file_3_of_Neutrophil-to-lymphocyte_ratio_as_a_prognostic_factor_for_patients_with_metastatic_or_recurrent_breast_cancer_treated_using_capecitabine_a_retrospective_study/18393327.  , 2022
 
?
14

Supplementary Figures – First-line Osimertinib in EGFR muta..:

Shigemasa Takamizawa (11680098) ; Yusuke Okuma (394608) ; Yasuhiro Kato (523643)...
https://figshare.com/articles/figure/Supplementary_Figures_First-line_Osimertinib_in_EGFR_mutation-positive_non-small_cell_lung_cancer_patients_with_poor_performance_status/16988260.  , 2021
 
?
15

Supplementary Table – First-line Osimertinib in EGFR mutati..:

Shigemasa Takamizawa (11680098) ; Yusuke Okuma (394608) ; Yasuhiro Kato (523643)...
https://figshare.com/articles/dataset/Supplementary_Table_First-line_Osimertinib_in_EGFR_mutation-positive_non-small_cell_lung_cancer_patients_with_poor_performance_status/16988269.  , 2021
 
1-15